TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two recent deaths involving counterfeit versions of investigational weight-loss drug retatrutide were reported to the FDA, according to a CBS News report cited by MedPage Today. Separately, Novo Nordisk says it plans to discontinue its liraglutide injection Saxenda in early 2027 because of declining sales; the source does not link the deaths to approved medicines.
Two recent deaths involving counterfeit versions of retatrutide, an investigational weight-loss drug, were reported to the U.S. Food and Drug Administration, according to CBS News as cited in an October 13 MedPage Today roundup. In a separate development, Novo Nordisk plans to discontinue Saxenda, its liraglutide weight-loss injection, in early 2027 because of declining sales; the report does not say the decision is related to the deaths.
The roundup gives few details about the deaths. It says the cases involved counterfeit retatrutide and were reported to the FDA, but does not identify the people who died, describe when or where the deaths occurred, or specify what the counterfeit products contained. It also does not establish whether retatrutide itself, another substance, or other circumstances contributed to the deaths. The report treats the cases as a warning about counterfeit products, not as confirmed evidence of a safety problem with an approved retatrutide medicine.
Retatrutide is described as an investigational medication, not an approved weight-loss drug. The same roundup notes that lawsuits continue to allege severe adverse events associated with GLP-1 receptor agonists, citing NPR. Lawsuit allegations are not findings that a drug caused an injury, and the brief report provides no details about the claims or their status.
Novo Nordisk’s planned Saxenda discontinuation is a distinct commercial development. The company said declining sales prompted plans to stop the liraglutide injection in early 2027. The roundup does not state whether the decision applies in every market, whether existing prescriptions will be affected before then, or what alternatives patients may be offered.
Counterfeit Drugs and Saxenda Access
The reports concern different issues: the deaths involve products described as counterfeit, while Saxenda’s planned withdrawal is attributed to declining sales. Keeping those developments separate matters for patients and clinicians. The FDA reports do not, on the information available here, show that an approved weight-loss medicine caused the deaths or that Saxenda is being discontinued for safety reasons.
Counterfeit injectable medicines can pose risks because buyers may not know what a product contains, how it was made, or whether it was stored and handled properly. The source does not identify the products’ ingredients or supply routes, so the particular hazards in these cases remain unknown. People considering weight-loss medication should discuss treatment with a licensed clinician and obtain prescription medicines through legitimate, regulated channels.
Saxenda’s planned discontinuation could affect patients who use liraglutide for weight management, particularly if they need time to discuss ongoing treatment with their clinician. The report offers no transition timetable or patient guidance. It also does not say that other liraglutide products or other medicines will be discontinued.
legitimate weight loss prescription medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Two Separate Drug Developments
The October 13 MedPage Today item is a short roundup of developments in endocrinology, not a detailed investigation of the deaths or a full company notice about Saxenda. Its retatrutide item attributes the death report to CBS News; its reference to lawsuits cites NPR. The limited format means the roundup does not provide case records, FDA findings, or direct quotations from regulators.
The item identifies retatrutide as investigational and Saxenda as a GLP-1 weight-loss injectable containing liraglutide. It reports no approval of retatrutide and makes no claim that the counterfeit products came from a specific seller or source. The planned Saxenda discontinuation, meanwhile, is presented as a business decision linked to declining sales.
The roundup also mentions other obesity-related developments, including new World Health Organization guidance advising against weight-loss drugs or bariatric surgery for children younger than 10. That item is separate from both the counterfeit-product reports and Saxenda’s planned discontinuation, and does not establish a connection between them.
“Two recent deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication, were reported to the FDA.”
— MedPage Today, citing CBS News
As an affiliate, we earn on qualifying purchases.
Details Behind the Death Reports
The source does not name the people who died, give the dates or locations of the deaths, identify the counterfeit products, or describe what they contained. It does not report autopsy findings, FDA conclusions, or evidence establishing a cause. The reported cases therefore cannot be used from this account alone to determine whether retatrutide, contamination, another ingredient, or unrelated factors were involved.
It is also unclear whether regulators have issued a public alert, identified a manufacturer or seller, or taken enforcement action. The roundup offers no information about the scope of distribution or whether additional cases have been reported. The cited lawsuits are described only as ongoing allegations, with no case-specific outcomes supplied.
For Saxenda, the source does not specify the markets affected, the exact final date of sale, or how patients and prescribers will be notified. It also does not say whether the discontinuation applies to other liraglutide formulations. Those details would be needed to assess the practical effect on current users.
saxenda alternative weight loss injections
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
FDA Findings and Saxenda Timeline
Further information would be needed from the FDA or other authorities to clarify the reported deaths, including what products were involved and whether investigators have identified a cause. Until those details are available, the cases should be described as deaths reported in connection with counterfeit versions, not as proof that an approved medicine caused harm.
Novo Nordisk’s stated plan points to a Saxenda discontinuation in early 2027. Patients using the injection should ask their prescriber or pharmacist about the current supply and treatment planning rather than stopping or changing medication without medical advice. The source provides no further company timetable or patient instructions.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is confirmed about the retatrutide deaths?
The report says two recent deaths involving counterfeit versions of investigational retatrutide were reported to the FDA. It gives no case details or confirmed cause of death.
Is retatrutide an approved weight-loss drug?
No. The source describes retatrutide as an investigational medication. It does not report that the drug has been approved for weight management.
Why is Saxenda being discontinued?
Novo Nordisk’s plan, as summarized in the report, is based on declining sales. The source does not cite a safety reason.
When is Saxenda expected to be discontinued?
The roundup says Novo Nordisk plans to discontinue the liraglutide injection in early 2027. It does not give an exact date or explain how the plan will apply across markets.
Do the death reports prove that GLP-1 medicines caused the deaths?
No. The source concerns counterfeit retatrutide products and does not establish a cause. It separately describes lawsuits alleging adverse events; allegations are not proof that a medicine caused an injury.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
